Disease · MONDO_0006835

minimal change disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. minimal change disease. Diseases, record MONDO_0006835. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006835

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: minimal change disease; Open Targets
Open Targets ID: MONDO_0006835; Open Targets
Other names: Minimal change disease (disorder), Nephrosis, Lipoid, Nephrotic syndrome with Lesion of Minimal Change Glomerulonephritis, Nephrotic syndrome with lesion of minimal change nephrotic syndrome, lipoid nephrosis, minimal change glomerulonephritis, minimal change nephropathy, nil disease; Open Targets
Disease Ontology: DOID:10966; Disease Ontology
MeSH: D009402; MeSH
NCI Thesaurus: C34844; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 6 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MYCOPHENOLIC ACID	CHEMBL866	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PREDNISONE	CHEMBL635	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RIPERTAMAB	CHEMBL4594604	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
TACROLIMUS	CHEMBL3989887	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
VALPROIC ACID	CHEMBL109	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ABATACEPT	CHEMBL1201823	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ATACICEPT	CHEMBL1742986	Protein	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets17

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
AGTR1	Type-1 angiotensin II receptor	1	Type-1 angiotensin II receptor antagonist	Phase 2	https://conductscience.org/library/genes/185	Drugs and targets
ALDH5A1	Succinate-semialdehyde dehydrogenase, mitochondrial	1	Succinate semialdehyde dehydrogenase inhibitor	Phase 2/3	https://conductscience.org/library/genes/7915	Drugs and targets
BTK	Tyrosine-protein kinase BTK	1	Tyrosine-protein kinase BTK inhibitor	Phase 2	https://conductscience.org/library/genes/695	Drugs and targets
CD80	T-lymphocyte activation antigen CD80	1	T-lymphocyte activation antigen CD80 inhibitor	Phase 2	https://conductscience.org/library/genes/941	Drugs and targets
CD86	T-lymphocyte activation antigen CD86	1	T-lymphocyte activation antigen CD86 inhibitor	Phase 2	https://conductscience.org/library/genes/942	Drugs and targets
EDNRA	Endothelin-1 receptor	1	Endothelin receptor ET-A antagonist	Phase 2	https://conductscience.org/library/genes/1909	Drugs and targets
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 3	https://conductscience.org/library/genes/2280	Drugs and targets
IMPDH1	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3614	Drugs and targets
IMPDH2	Inosine-5'-monophosphate dehydrogenase (IMPDH)	1	Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor	Phase 3	https://conductscience.org/library/genes/3615	Drugs and targets

1 to 10 of 17

See all 17 targets

Trials13

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02592798	Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)	Phase 2	36	2021-03-05	Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease	ABATACEPT	Its record names the disease	ClinicalTrials.gov
NCT00098020	Podocyte Retinoids	Phase 2	12	2017-12-13	Collapsing Glomerulopathy, Glomerulosclerosis, Focal Segmental	ISOTRETINOIN	Its record names the disease	ClinicalTrials.gov
NCT00065611	Steroid Treatment for Kidney Disease	Phase 3	8	2011-10-28	Nephrosis, Focal Lipoid Glomerulosclerosis	DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT04009668	Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease	Phase 2	7	2024-10-30	FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease	ADALIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT06983028	Atacicept in Multiple Glomerular Diseases	Phase 2	250		pMN, IgAN, Nephrotic Syndrome, MCD, FSGS	ATACICEPT	Its record names the disease	ClinicalTrials.gov
NCT01197040	Evaluation of Low Dose Corticosteroids Efficiency, Associated With Myfortic ® in the Treatment of Nephrotic Syndrome	Phase 3	117		Nephrotic Syndrome	MYCOPHENOLIC ACID, PREDNISONE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT06500702	A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease	Phase 2	84		Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion	BRIVEKIMIG, FREXALIMAB, RILZABRUTINIB	Its record names the disease	ClinicalTrials.gov
NCT06405100	Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD	Phase 3	81		Minimal Change Disease	RIPERTAMAB, TACROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT05003986	Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases	Phase 2	67		Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome	SPARSENTAN	Its record names the disease	ClinicalTrials.gov
NCT03298698	Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome	Phase 3	40		Idiopathic Nephrotic Syndrome, Minimal Change Disease, Focal Segmental Glomerulosclerosis	RITUXIMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 13

See all 13 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
2 Doses Every 2 Weeks Arm vs 4 Doses Every 4 Weeks Arm: serious adverse events	1 of 4	2 of 4	8	NCT00065611

Source Trial comparisons

Papers from its trials10

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42384439	DERIVED	1	PubMed
40938675	DERIVED	1	PubMed
40337980	DERIVED	1	PubMed
39899371	DERIVED	1	PubMed
39808779	DERIVED	1	PubMed
38724717	DERIVED	3	PubMed
35230699	DERIVED	3	PubMed
35224732	DERIVED	3	PubMed
30385039	DERIVED	1	PubMed
24480824	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006835

GET https://conductscience.org/api/diseases/v1/MONDO_0006835/drugs

API reference For AI assistants